ELUT
NASDAQElutia Inc.
Price$1.04+0.00 (+0.48%)
01:45 PM07:45 PM
News · 26 weeks49+120%
2025-12-282026-06-21
Mix2190d
- Insider10(48%)
- Other5(24%)
- SEC Filings4(19%)
- Earnings2(10%)
Latest news
25 items- INSIDERPRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,064 shares, increasing direct ownership by 3% to 441,180 units (SEC Form 4) to cover taxes4 - ELUTIA INC. (0001708527) (Issuer)
- SECElutia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- INSIDERSEC Form 4 filed by Director Rakin Kevin4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Colpman David4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Makes Brigid4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Neels Guido J4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 118,052 units (SEC Form 4) (tax liability)4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,485 shares, increasing direct ownership by 2% to 480,082 units (SEC Form 4) (tax withholding)4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERPRESIDENT AND CEO Mills C Randal covered exercise/tax liability with 9,718 shares and converted options into 27,083 shares, increasing direct ownership by 4% to 426,771 units (SEC Form 4) (tax liability)4 - ELUTIA INC. (0001708527) (Issuer)
- PRElutia to Present at Planet MicroCap Showcase 2026 on June 17thGAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17–18, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix te
- INSIDERDirector Rakin Kevin gifted 70,000 shares and disposed of 50,000 shares, decreasing direct ownership by 36% to 126,120 units (SEC Form 4)4 - ELUTIA INC. (0001708527) (Issuer)
- PRA Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
- PRElutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The award was approved by the independent Compensation Committee of the Board of Directors and was granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the one new employee received an aggregate of 48,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with the balance ves
- SECElutia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- PRElutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery MarketNXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparationsBrought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scaleChief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunityStrong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestitureConference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported a business update and financial res
- PRElutia to Present at the 16th Annual LD Micro Invitational on May 18thGAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluti
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- PRElutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the op
- SECSEC Form DEFA14A filed by Elutia Inc.DEFA14A - ELUTIA INC. (0001708527) (Filer)
- SECSEC Form DEF 14A filed by Elutia Inc.DEF 14A - ELUTIA INC. (0001708527) (Filer)
- INSIDERSEC Form 4 filed by Neels Guido J4 - ELUTIA INC. (0001708527) (Issuer)
- SECSEC Form S-8 filed by Elutia Inc.S-8 - ELUTIA INC. (0001708527) (Filer)
- PRElutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology desi
- SECSEC Form 10-K filed by Elutia Inc.10-K - ELUTIA INC. (0001708527) (Filer)
- PRElutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with th
ELUT FAQ
5 questionsWhere does ELUT stock trade?
Elutia Inc. (ELUT) is listed on NASDAQ.What sector and industry is ELUT in?
Elutia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Elutia Inc. go public?
Elutia Inc. (ELUT) completed its IPO in 2020.What companies are similar to ELUT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ELUT side-by-side with any of them on Quantisnow.How can I track ELUT on Quantisnow?
Quantisnow aggregates Elutia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELUT to receive live email and push alerts on every new disclosure.